FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
	Data of Danagit
Express Mail Label Number	Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1634

KUDARAVALLI ET AL.

Examiner: Pohnert, Steven

С

INTERNATIONAL APPLICATION NO: PCT/EP03/10798

FILED: 29 SEPTEMBER 2003

U.S. APPLICATION NO: 10/529,613

35 USC §371 DATE: 30 MARCH 2005

FOR: METHODS TO TREAT CHOLESTEROL ELEVATIONS DURING

IMMUNOSUPPRESSANT THERAPY

MS: Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed October 5, 2005. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Leslie Fischer

Attorney for Applicants

Reg. No. 58,393

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 101 East Hanover, NJ 07936-1080 (862) 778-9308

Date:

2/26/09